养老院中的抗胆固醇负担和认知障碍:四种抗胆固醇量表的比较
Alessio Novella1, Chiara Elli1, Aladar Ianes2
1Laboratory of Clinical Pharmacology and Appropriateness of Drug Prescription, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan, Italy.
Drugs & aging
|August 24, 2023
概括
在养老院使用的抗胆固醇药物会损害认知能力. 抗胆性认知负担 (ACB) 尺度有效地识别了有风险的居民,显示较高的负担与显著的认知衰退相关.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 认知科学 认知科学
背景情况:
- 养老院居民经常使用具有抗胆作用的药物.
- 这些药物对认知的累积影响是一个重大问题.
研究的目的:
- 用四个尺度来评估认知功能和抗胆固醇负担之间的关系.
- 测试假设抗胆固醇负担增加与较差的认知表现有关.
主要方法:
- 一个回顾性,横截面,多中心研究在意大利的养老院.
- 收集的社会人口统计数据,诊断和药物治疗;使用迷你精神状态检查 (MMSE) 评估认知状态.
- 分析了抗胆固醇负担及其与认知衰退和死亡率的关联,使用回归模型,调整混因素.
主要成果:
- 较高的抗胆固醇负担和认知障碍之间的直接关系仅在抗胆固醇认知负担 (ACB) 尺度上被确定.
- 在ACB尺度上得分为5或以上的居民在MMSE得分下降2.5分以上 (p < 0.001).
- 在没有痴呆症的住户中观察到ACB尺度和抗胆固醇风险尺度的关系趋势;没有发现与死亡率的关联.
结论:
- 抗胆固醇药物的累积作用可能会对养老院居民的认知表现产生负面影响.
- 该ACB尺度是一个有价值的工具,用于识别可能受益于减少抗胆固醇负担的居民.
- 针对ACB尺度特别证实了抗胆固醇负担和认知障碍之间的直接联系.
相关概念视频
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
715
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
715
Alzheimer's Disease: Treatment
213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
152
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
152
Parkinson's Disease: Treatment
297
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
297
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Alzheimer's Disease: Overview
518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518


